Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Eftrenonacog-alfa/eptacog-alfa

Drug resistance and ischaemic cerebellar infarction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Comerford C, et al. Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, et al. recombinant factor IX Fc fusion protein. Haemophilia 27: e484-e486, No. 4, Jul 2021. Available from: URL: http://onlinelibrary.wiley.com Comerford C, et al. Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, et al. recombinant factor IX Fc fusion protein. Haemophilia 27: e484-e486, No. 4, Jul 2021. Available from: URL: http://​onlinelibrary.​wiley.​com
Metadaten
Titel
Eftrenonacog-alfa/eptacog-alfa
Drug resistance and ischaemic cerebellar infarction: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41842-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Alendronic-acid

Case report

Cinacalcet

Case report

Tacrolimus